Share This Page
Suppliers and packagers for VYONDYS 53
✉ Email this page to a colleague
VYONDYS 53
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Sarepta Theraps Inc | VYONDYS 53 | golodirsen | SOLUTION;INTRAVENOUS | 211970 | NDA | Sarepta Therapeutics, Inc. | 60923-465-02 | 1 VIAL, SINGLE-USE in 1 CARTON (60923-465-02) / 2 mL in 1 VIAL, SINGLE-USE | 2019-12-12 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Vyondys 53
Introduction
Vyondys 53, also known by its generic name golodirsen, is a groundbreaking therapeutic approved by the U.S. Food and Drug Administration (FDA) for the treatment of Duchenne Muscular Dystrophy (DMD) in patients with specific genetic mutations. As a novel antisense oligonucleotide, its manufacturing and supply chain are critical to ensuring accessibility for patients globally. This analysis explores the primary suppliers involved in the production of Vyondys 53, their roles, market positioning, and implications for stakeholders.
Overview of Vyondys 53 and its Manufacturing Complexity
Vyondys 53 employs phosphorodiamidate morpholino oligomer (PMO) chemistry, a synthetic molecule designed to modify gene expression. The complexity of its synthesis demands high-precision manufacturing facilities compliant with Good Manufacturing Practices (GMP). The production involves multiple sophisticated steps including chemical synthesis, purification, formulation, and packaging, often requiring a network of specialized suppliers.
Key Suppliers in the Vyondys 53 Supply Chain
1. Oligonucleotide Synthesis Manufacturers
At the core of Vyondys 53’s supply chain are suppliers producing the oligonucleotide components. These molecules are central to its mechanism, facilitating exon skipping in the dystrophin gene.
-
Surgical, chemical, and intellectual property considerations often restrict the number of capable manufacturers. Leading players include:
- Sangamo Therapeutics: Historically involved in oligonucleotide synthesis for genetic medicines; may license or produce components directly or through partnerships.
- BioSpring (a part of Wacker Chemie AG): Known for custom phosphorodiamidate morpholino oligonucleotide (PMO) production, specialized in high-quality oligonucleotide synthesis for therapeutic use.
- Alnylam Pharmaceuticals: While primarily focused on siRNA, collaborates with oligonucleotide manufacturers for certain antisense molecules.
-
Key Considerations:
- These manufacturers must adhere to stringent GMP standards and ensure batch-to-batch consistency to meet FDA approval requirements.
2. Formulation and Packaging Suppliers
Post-synthesis, the oligonucleotides are formulated into injectable solutions and packaged for distribution.
-
Leading Formulation Specialists:
- Thermo Fisher Scientific: Offers manufacturing services for high-purity biomolecules, including sterile filling and packaging of oligonucleotides and related pharmaceuticals.
- Baxalta (a division of Takeda): Has capabilities in sterile formulation of complex biologics, possibly involved in the final Vyondys 53 formulation process.
-
Packaging Suppliers:
- West Pharmaceutical Services: Supplies sterile vials, stoppers, and seals tailored for sensitive oligonucleotide therapeutics.
3. Contract Manufacturing Organizations (CMOs)
Many biotech firms utilize CMOs for scalable production, quality control, and regulatory compliance.
- Catalent Pharma Solutions:
- Provides formulation, clinical trial material manufacturing, and commercial-scale production services.
- Lonza:
- Known for custom oligonucleotide synthesis and sterile manufacturing, including large-scale production aligned with regulatory standards.
4. Distribution and Cold Chain Logistics
Oligonucleotide therapies require cold chain management to maintain stability.
- Supply Chain Partners:
- UPS Healthcare and FedEx Express: Offer specialized temperature-controlled logistics solutions.
- Vaccine and biopharmaceutical logistics specialists: Ensure shipment integrity from manufacturing plants to healthcare providers.
Competitive and Regulatory Considerations
The supply of Vyondys 53 is limited by the capacity of specialized oligonucleotide manufacturers. Market entry barriers are high due to the technical expertise, GMP compliance, and intellectual property rights involved. Regulatory agencies demand comprehensive validation of manufacturing processes, constant quality assurance, and traceability.
In light of these factors, Pfizer, the developer of Vyondys 53, may partner with only select high-capacity, highly compliant manufacturers to meet global demand. Such partnerships are crucial to mitigate supply shortages, especially given the orphan status and limited patient population.
Implications for Stakeholders
-
Manufacturers:
Engaging with a limited pool of oligonucleotide producers means high entry barriers but also opportunity for strategic partnerships. Firms with proven GMP track records and innovation in oligonucleotide synthesis can secure long-term contracts. -
Healthcare Providers and Patients:
Reliance on a constrained supply chain emphasizes the importance of stability and contingency planning. Ensuring diversified supplier relationships reduces risk of shortages and ensures consistent patient access. -
Regulatory Authorities:
Continuous oversight is necessary to certify manufacturing quality, monitor capacity constraints, and approve facility changes.
Future Outlook
The gene therapy landscape is rapidly evolving, with increasing capacity for high-fidelity oligonucleotide synthesis. As competition intensifies and manufacturing technology advances, the supply chain for drugs like Vyondys 53 is expected to become more resilient. Strategic investments by pharmaceutical companies in expanding manufacturing capacity and fostering collaborations with innovative oligonucleotide producers will be key to meeting future demand.
Key Takeaways
- Specialized production: Vyondys 53’s production hinges on high-complexity oligonucleotide synthesis, limited to a few experienced GMP-compliant manufacturers.
- Strategic partnerships: Pfizer, the developer, likely partners with industry leaders like BioSpring, Lonza, and Thermo Fisher Scientific to secure supply.
- Regulatory compliance: Manufacturing sources must adhere to stringent GMP standards to meet FDA approval and maintain quality.
- Supply chain resilience: Dependence on a limited set of suppliers highlights the need for diversified and scalable manufacturing capabilities.
- Emerging technology: Advances in oligonucleotide synthesis methods will enhance supply stability, reduce costs, and expand access.
FAQs
1. Who are the primary manufacturers involved in producing Vyondys 53?
Leading producers include BioSpring, Lonza, and Thermo Fisher Scientific, each offering specialized GMP-compliant oligonucleotide synthesis and formulation services.
2. How does the complexity of oligonucleotide manufacturing impact supply stability?
The specialized, high-precision processes restrict the number of capable manufacturers, potentially leading to supply bottlenecks, especially during increased demand or manufacturing disruptions.
3. Are there plans to expand manufacturing capacity for Vyondys 53?
While specific expansion plans are proprietary, industry trends suggest ongoing investments to increase capacity at existing facilities and develop new manufacturing technologies to meet future demand.
4. What role do contract manufacturing organizations play in the supply chain?
CMOs like Catalent and Lonza handle large-scale synthesis, formulation, and packaging, enabling pharmaceutical companies to scale production efficiently while maintaining compliance.
5. How does regulation influence the suppliers of Vyondys 53?
Strict adherence to GMP, validation processes, and quality control standards are mandatory, limiting supplier options but ensuring high product quality and patient safety.
References
[1] U.S. Food and Drug Administration. FDA approves first-ever drug for Duchenne muscular dystrophy. 2019.
[2] Pfizer. Vyondys 53 (golodirsen) Prescribing Information. 2019.
[3] Lonza. Oligonucleotide manufacturing services. 2022.
[4] BioSpring, Wacker Chemie AG. Custom oligonucleotide synthesis capabilities. 2022.
[5] Thermo Fisher Scientific. Oligonucleotide synthesis and biologic manufacturing. 2023.
More… ↓
